CRISPR Therapeutics AG (CRSP) Other Non-Current Assets (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Other Non-Current Assets data on file, last reported at $7.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets fell 5.07% year-over-year to $7.6 million; the trailing twelve-month figure through Mar 2026 stood at $7.6 million (down 5.07% YoY), and the FY2025 full-year result was $24.4 million, up 53.95% from the prior year.
• Other Non-Current Assets retreated to $7.6 million in Q1 2026, from $24.4 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $24.4 million in Q4 2025 to a low of $7.6 million in Q1 2026.
• A 5-year average of $12.8 million and a median of $11.7 million in 2023 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets slumped 32.91% in 2022 and soared 111.01% in 2025, its largest moves.
• Tracing CRSP's Other Non-Current Assets over 5 years: stood at $11.6 million in 2022, then fell by 0.38% to $11.6 million in 2023, then soared by 36.56% to $15.8 million in 2024, then soared by 53.95% to $24.4 million in 2025, then tumbled by 68.81% to $7.6 million in 2026.
• Business Quant data shows CRSP's Other Non-Current Assets at $7.6 million in Q1 2026, $24.4 million in Q4 2025, and $24.3 million in Q3 2025.